Researchers are studying small molecules therapies which can stop Aβ42-fibrinogen interaction to prevent clot structures result in less oxygen to brain cells as a potential therapy for AD disease (a type of amyloid-β, called Aβ42, reacts with fibrinogen leading to oligomeric clots and deterioration of memory and cognitive ability).
References:
H. J. Ahn, D. Zamolodchikov, M. Cortes-Canteli, E. H. Norris, J. F. Glickman, S. Strickland. Alzheimer's disease peptide -amyloid interacts with fibrinogen and induces its oligomerization. Proceedings of the National Academy of Sciences,
No comments:
Post a Comment